The evidence is clear: vaccines are one of the most cost-effective investments in health and development in history. Gavi helps save children’s lives and protect people’s health by increasing equitable use of vaccines in lower-income countries.

Over 10 million future deaths averted

Since its inception in 2000, Gavi has helped developing countries to prevent more than 10 million future deaths through its support for routine immunisation programmes and vaccination campaigns.

Source: WHO/UNICEF; Gavi, the Vaccine Alliance 2018

More than 700 million children immunised

Since 2000, Gavi support has contributed to the immunisation of more than 700 million children.

Source: WHO/UNICEF 2018

80% coverage with DTP3

Coverage with three doses of diphtheria-tetanus-pertussis-containing vaccine (DTP3), including pentavalent vaccine, in Gavi-supported countries was 80% in 2017 – just 5 percentage points below the global average. While this represents an increase of 21 percentage points since 2000, it has remained unchanged over the past two years.

Source: WHO/UNICEF 2018

65 million children immunised in 2017

In 2017 alone, 65 million children were immunised with Gavi-supported vaccines. This equates to more than 190 million points of contact between these children and the primary health system and provides a robust platform for other health interventions.

Source: WHO/UNICEF 2018

Health systems and immunisation services strengthened in more than 60 countries

The Vaccine Alliance has helped to strengthen health systems and immunisation services in more than 60 countries.

Source: Gavi, the Vaccine Alliance

More than 430 vaccine introductions by the end of 2018

Gavi has supported more than 430 vaccine introductions and campaigns since 2000.

Source: Gavi, the Vaccine Alliance

Return on investment of immunisation in Gavi-supported countries1: US$ 18 for every US$ 1 spent

A study in Health Affairs covering 73 Gavi-supported countries over the 2011–2020 period shows that, for every US$ 1 spent on immunisation, US$ 18 are saved in healthcare costs, lost wages and lost productivity due to illness. If we take into account the broader benefits of people living longer, healthier lives, the return on investment rises to US$ 48 per US$ 1 spent.

Source: Johns Hopkins University 2016

Over US$ 150 billion generated in economic benefits

By preventing illness, death and long-term disability, Gavi-supported vaccines have helped to generate more than US$ 150 billion in economic benefits since 2000.

Source: Constenla et al. Estimating the economic impact of vaccinations in 73 resource-constrained countries, 2001–2030

Fifteen countries have transitioned out of Gavi support

By early 2019, 15 countries had started to fully self-finance all their vaccines introduced with Gavi support.2  

Source: Gavi, the Vaccine Alliance

1Note: The study also looked at the return on investment in the world’s 94 lowest-income countries. For every US$ 1 spent in these countries, US$ 16 are saved in healthcare costs, lost wages and lost productivity. Adding the broader benefits of immunisation, this rises to US$ 44 for every dollar invested.
2 Does not include countries that have previously received Gavi support but did not transition under the current policy (Albania, Bosnia-Herzegovina, China, Turkmenistan and Ukraine).

Gavi supports 13 vaccines

Pentavalent vaccine: 73 countries, 404 million children, 5 antigens

In July 2014, South Sudan became the final Gavi-supported country to introduce the five-in-one pentavalent vaccine. By the end of 2017, 404 million children had been immunised with pentavalent vaccine with Gavi support.

Over 143 million children vaccinated against pneumococcal disease

By the end of 2017, 58 countries had immunised more than 143 million children against pneumococcal disease with support from the Vaccine Alliance.

More than 76 million children vaccinated against rotavirus

Our support has contributed to immunising over 76 million children against rotavirus diarrhoea. By the end of 2017, 43 countries had introduced the vaccine with support from the Vaccine Alliance.

Over 279 million people reached by meningitis A campaigns

By the end of 2017, 21 countries in the African meningitis belt had immunised over 279 million people against meningitis A through Gavi-supported campaigns. Seven countries had introduced the vaccine into their national immunisation systems.

Meningitis A, C, W, Y combination vaccine stockpile prevents outbreaks

Gavi funds a stockpile of multivalent vaccine to prevent outbreaks of meningitis A, C, W and Y. By the end of 2017, over 21 million vaccine doses had been distributed through the stockpile. 

More than 1.5 million girls reached with human papillomavirus vaccine

Since the first human papillomavirus (HPV) vaccine demonstration programme in Kenya in 2013, more than 1.5 million girls have been immunised with Gavi support.

Typhoid vaccine: new funding window

The Gavi Board approved support for a new typhoid vaccine at the end of 2017. The first country introductions are expected to start in early 2019.

75 million children immunised against polio

In September 2014, Nepal became the first country to introduce inactivated polio vaccine (IPV) with Gavi support. By the end of 2017, 55 countries had introduced the vaccine with our support, collectively immunising more than 75 million children.

52 million reached with a second dose of measles vaccine

Since 2007, countries have immunised 52 million children with a second dose of measles vaccine and 15 million with a first dose of measles-rubella vaccine through Gavi-supported routine immunisation programmes. Gavi-funded campaigns with these two vaccines have helped to vaccinate another 370 million children in countries at high risk of outbreaks. 

Yellow fever vaccine: mass prevention campaigns and routine immunisation

Since 2011, Gavi-supported campaigns have protected over 98 million people in 14 countries. We have also helped 17 countries introduce yellow fever vaccine through routine immunisation, immunising more than 100 million children.

Oral cholera vaccine stockpile: over 18 million doses distributed

Since its creation in 2013, the Gavi-supported global oral cholera vaccine stockpile has distributed over 18 million doses to 18 countries. In 2017, nine countries – Bangladesh, Cameroon, Haiti, Malawi, Mozambique, Nigeria, Sierra Leone, Somalia and South Sudan – accessed the stockpile.

Over 17 million children vaccinated against Japanese encephalitis

In April 2015, Lao People’s Democratic Republic became the first country to introduce Japanese encephalitis (JE) vaccine with Gavi funding. By the end of 2017, close to 920,000 children had been immunised against JE through Gavi-supported routine programmes, while more than 17 million had been reached through vaccination campaigns.

Sources: WHO/UNICEF and Gavi, the Vaccine Alliance, 2018.

While we continue to help countries introduce new vaccines, our focus is expanding. Our task now is to reach every child with these vaccines, regardless of where they are born or how rich their families are, and whether they are boys or girls.

1.5 million children under five lose their lives to vaccine-preventable diseases every year

In 2012, approximately 6.6 million children worldwide died before the age of five. WHO estimates that 1.5 million of these deaths were due to vaccine-preventable diseases.

Source: WHO

19.9 million underimmunised

19.9 million infants remain underimmunised with three doses of DTP in the world each year. One in five of all children in Gavi-supported countries miss out on a full course of this basic package of vaccines.

Source: WHO/UNICEF 2018

93% of children in Gavi-supported countries miss out on recommended vaccines

Only 7% of children in Gavi-supported countries have access to all 11 vaccines recommended by WHO for infants in all countries.

Source: WHO/UNICEF, UNDP 2017

Focus on 20 priority countries

In the 2016–2020 period we are intensifying our efforts in 20 priority countries. Ten of these – Afghanistan, Chad, the Democratic Republic of the Congo, Ethiopia, India, Indonesia, Kenya, Nigeria, Pakistan and Uganda – account for over 70% of the underimmunised children in Gavi-supported countries, so improving their immunisation coverage is critical.

We are also prioritising an additional 10 countries, which face severe inequities or crises: the Central African Republic, Haiti, Madagascar, Mozambique, Myanmar, Niger, Papua New Guinea, Somalia, South Sudan and Yemen.

Source: WHO/UNICEF 2017

Over a quarter of child deaths are due to pneumonia and diarrhoea

Pneumonia and diarrhoea account for 28% of deaths in under-fives in Gavi-supported countries.

Source: MCEE-WHO 2016

Gender barriers can prevent children from being immunised

A WHO study found no significant difference in immunisation coverage rates for boys and girls at the global level. Yet in some societies boys are privileged over girls. In others, the opposite is true and girls have greater access to vaccines than boys. In societies where women have low status and therefore lack access to immunisation and other health services, both girls and boys are less likely to be immunised.

Source: WHO

One woman dies every 2 minutes from cervical cancer

One woman dies from cervical cancer approximately every two minutes – or 311,000 a year – over 80% in developing countries. If current trends hold, and without changes in prevention and control, cervical cancer deaths could eventually outpace maternal deaths. HPV vaccines can prevent up to 90% of all cervical cancer cases.

Source: WHO

100,000 babies born with birth defects due to rubella

Every year, 100,000 babies are born with severe birth defects known as congenital rubella syndrome because their mothers were infected with rubella during pregnancy – the vast majority in Gavi-supported countries. The combined measles-rubella vaccine, which Gavi supports, can prevent this devastating disease.

Source: PLOS ONE 2016

Pentavalent, pneumococcal and rotavirus vaccines: 52% reduction since 2010

The total cost of fully immunising a child with pentavalent, pneumococcal and rotavirus vaccines fell by over 52% from US$ 35 in 2010 to US$ 16.63 in 2017.

Pentavalent (DTP-hep B-Hib) vaccine: a reduction of 82% to US$ 0.88 per dose

The weighted average price of pentavalent vaccine per dose dropped from US$ 2.98 in 2010 to US$ 0.88 in 2017, and is expected to decrease further to US$ 0.79 by 2019.

Human papillomavirus (HPV) vaccine: two-thirds reduction to US$ 4.50

In 2013, a price of US$ 4.50 per dose for one type of HPV vaccine was agreed – a two-thirds reduction on the previous lowest public price. The rise in country demand for the vaccine is currently outpacing supply. Gavi is working with countries to help adjust the timing of introductions and with manufacturers to scale up production capacity.

Inactivated polio vaccine (IPV): ensuring sufficient supply

After a period of supply shortages, sufficient quantities of IPV are now available to cover routine demand in Gavi-supported countries. While an important price increase was seen in 2019, the weighted average price is expected to drop with the arrival of new suppliers in the 2020–21 period.

Pneumococcal vaccines through the AMC: less than 5% of the US public price

Through the Advance Market Commitment (AMC), pneumococcal vaccines are available to Gavi-supported countries at no more than US$ 3.50 per dose – less than 5% of the public price in the USA. By early 2019, Gavi had secured a lowest price offer from one of its pneumococcal vaccine suppliers of US$ 2.90 per dose.

Manufacturing base grown from 5 to 17 – more than half based in Africa, Asia and Latin America

2001: 5 vaccine manufacturers producing prequalified, appropriate Gavi vaccines – 1 based in Africa

2017: 17 vaccine manufacturers producing prequalified, appropriate Gavi vaccines – 11 based in Africa, Asia and Latin America.

Rotavirus vaccine: lowest price of US$ 0.85 per dose

Thanks to long-term supply agreements with manufacturers, Gavi has been able to secure prices below US$ 1 per dose for two types of rotavirus vaccine (US$ 0.85 and US$ 0.95 per dose, respectively). This is less than 2% of the 2019 public price in the USA (US$ 70.49 per dose). However, supply constraints are disrupting the efforts of some governments to introduce the vaccine in 2018/2019.

Sources: Gavi, the Vaccine Alliance, UNICEF Supply Division and CDC vaccine price list, 2018.

Accelerating impact

Between 2016 and 2020, Gavi will help countries to immunise another 300 million children against potentially fatal diseases, saving between 5 and 6 million lives in the long term.

Towards universal health coverage

Routine immunisation currently reaches 85% of the world’s children. It is the only intervention that brings the vast majority of families into contact with the health system five or more times during the first year of a child’s life. If we expand this reach further, we have a solid platform for universal health coverage.

19 countries to transition out of Gavi support by the end of 2020

Gavi continues to help countries to build sustainable immunisation programmes. Fifteen countries have already started to fully self-finance all their vaccines introduced with Gavi funding. By the end of 2020, a total of 19 countries are expected to have transitioned out of our support.

Vaccines prevent poverty

According to a study published in Health Affairs in 2018, vaccines administered between 2016 and 2030 will prevent 24 million people in 41 of the world's poorest countries from falling into poverty.

Source: Harvard University 2018

Sources of data: Gavi, the Vaccine Alliance, and WHO/UNICEF, 2018, unless otherwise stated.
close icon

modal window here